Fonar ROE 2006-2019 | FONR
Current and historical return on equity (ROE) values for Fonar (FONR) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Fonar ROE for the three months ending March 31, 2019 was 17.82%.
| Fonar ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2019-03-31 | $0.02B | $0.11B | 17.55% |
| 2018-12-31 | $0.02B | $0.11B | 17.48% |
| 2018-09-30 | $0.02B | $0.11B | 19.39% |
| 2018-06-30 | $0.02B | $0.10B | 20.49% |
| 2018-03-31 | $0.02B | $0.09B | 18.18% |
| 2017-12-31 | $0.02B | $0.09B | 22.75% |
| 2017-09-30 | $0.02B | $0.09B | 24.28% |
| 2017-06-30 | $0.02B | $0.08B | 25.94% |
| 2017-03-31 | $0.02B | $0.08B | 28.04% |
| 2016-12-31 | $0.02B | $0.07B | 25.20% |
| 2016-09-30 | $0.02B | $0.07B | 24.90% |
| 2016-06-30 | $0.02B | $0.06B | 26.32% |
| 2016-03-31 | $0.01B | $0.06B | 25.69% |
| 2015-12-31 | $0.01B | $0.06B | 25.12% |
| 2015-09-30 | $0.01B | $0.05B | 23.88% |
| 2015-06-30 | $0.01B | $0.05B | 22.45% |
| 2015-03-31 | $0.01B | $0.05B | 20.94% |
| 2014-12-31 | $0.01B | $0.05B | 21.39% |
| 2014-09-30 | $0.01B | $0.05B | 22.35% |
| 2014-06-30 | $0.01B | $0.05B | 23.39% |
| 2014-03-31 | $0.01B | $0.04B | 24.54% |
| 2013-12-31 | $0.01B | $0.04B | 23.23% |
| 2013-09-30 | $0.01B | $0.04B | 25.20% |
| 2013-06-30 | $0.01B | $0.04B | 28.00% |
| 2013-03-31 | $0.00B | $0.04B | 21.92% |
| 2012-12-31 | $0.00B | $0.01B | 32.65% |
| 2012-09-30 | $0.00B | $0.01B | 36.36% |
| 2012-06-30 | $0.00B | $0.01B | 42.11% |
| 2012-03-31 | $0.00B | $0.01B | 36.36% |
| 2011-12-31 | $0.00B | $0.01B | 57.14% |
| 2011-09-30 | $0.00B | $0.01B | 150.00% |
| 2011-06-30 | $0.00B | $0.01B | -200.00% |
| 2011-03-31 | $0.00B | $-0.00B | -50.00% |
| 2010-12-31 | $0.00B | $-0.00B | -19.05% |
| 2010-09-30 | $-0.00B | $-0.01B | 17.39% |
| 2010-06-30 | $-0.00B | $-0.01B | 52.17% |
| 2010-03-31 | $-0.00B | $-0.01B | 60.00% |
| 2009-12-31 | $-0.00B | $-0.01B | 47.06% |
| 2009-09-30 | $0.00B | $-0.01B | 0.00% |
| 2009-06-30 | $0.00B | $-0.00B | -53.33% |
| 2009-03-31 | $-0.01B | $-0.00B | 125.00% |
| 2008-12-31 | $-0.01B | $-0.00B | 360.00% |
| 2008-09-30 | $-0.01B | $-0.01B | 5600.00% |
| 2008-06-30 | $-0.01B | $-0.00B | -430.77% |
| 2008-03-31 | $-0.02B | $0.00B | -246.15% |
| 2007-12-31 | $-0.02B | $0.01B | -180.00% |
| 2007-09-30 | $-0.02B | $0.01B | -131.03% |
| 2007-06-30 | $-0.03B | $0.01B | -129.87% |
| 2007-03-31 | $-0.03B | $0.02B | -102.04% |
| 2006-12-31 | $-0.03B | $0.02B | -90.76% |
| 2006-09-30 | $-0.03B | $0.03B | -77.14% |
| 2006-06-30 | $-0.03B | $0.03B | -72.96% |
| 2006-03-31 | $-0.02B | $0.04B | -44.20% |
| 2005-12-31 | $-0.01B | $0.04B | -26.67% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.139B | $0.082B |
| FONAR Corporation is a developer and manufacturer of MRI scanners. The Company has introduced the world's first commercial MRI in 1980, and went public in 1981. FONAR's stellar product is the UPRIGHT MRI, also known as the Stand-Up MRI, the whole-body MRI that performs Position imaging and scans patients in numerous weight-bearing positions like standing, sitting, in flexion and extension, as well as the conventional lie-down position. The Company's subsidiary, Health Management Corporation of America, is a physician practice management company providing management services to medical providers. FONAR Corporation is based in Melville, New York. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $147.856B | 28.70 |
| Medtronic (MDT) | Ireland | $133.874B | 19.12 |
| Stryker (SYK) | United States | $76.669B | 27.36 |
| Boston Scientific (BSX) | United States | $59.033B | 28.30 |
| Baxter (BAX) | United States | $41.839B | 26.37 |
| EssilorLuxottica Societe Anonyme (ESLOY) | France | $29.060B | 0.00 |
| Coloplast (CLPBY) | Denmark | $25.618B | 40.90 |
| Zimmer Biomet Holdings (ZBH) | United States | $24.965B | 16.04 |
| Lonza Group Ag (LZAGY) | Switzerland | $24.947B | 0.00 |
| Terumo (TRUMY) | Japan | $23.393B | 26.90 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $19.274B | 0.00 |
| ResMed (RMD) | United States | $17.745B | 33.90 |
| Canopy Growth (CGC) | Canada | $12.161B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $12.027B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.308B | 49.34 |
| William Demant Holdings (WILYY) | Denmark | $7.651B | 0.00 |
| Insulet (PODD) | United States | $7.203B | 524.78 |
| Aurora Cannabis (ACB) | Canada | $7.109B | 70.10 |
| Perrigo (PRGO) | Ireland | $7.004B | 11.84 |
| Hill-Rom Holdings (HRC) | United States | $6.993B | 21.20 |
| GN STORE NORD (GNNDY) | Denmark | $6.409B | 32.73 |
| Haemonetics (HAE) | United States | $6.325B | 51.63 |
| ICU Medical (ICUI) | United States | $5.135B | 30.64 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $5.057B | 0.00 |
| Neogen (NEOG) | United States | $3.349B | 54.45 |
| NuVasive (NUVA) | United States | $2.982B | 24.36 |
| Hutchison China MediTech (HCM) | China | $2.925B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $2.711B | 0.00 |
| National Vision Holdings (EYE) | United States | $2.420B | 51.57 |
| Quidel (QDEL) | United States | $2.309B | 23.96 |
| Cardiovascular Systems (CSII) | United States | $1.598B | 917.80 |
| Aphria (APHA) | $1.579B | 0.00 | |
| Phibro Animal Health (PAHC) | United States | $1.229B | 18.41 |
| AtriCure (ATRC) | United States | $1.218B | 0.00 |
| VAREX IMAGING (VREX) | United States | $1.187B | 25.19 |
| Lantheus Holdings (LNTH) | United States | $1.089B | 28.93 |
| NanoString Technologies (NSTG) | United States | $1.056B | 0.00 |
| PetIQ (PETQ) | United States | $0.994B | 24.14 |
| MacroGenics (MGNX) | United States | $0.777B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.765B | 21.47 |
| Cerus (CERS) | United States | $0.758B | 0.00 |
| Quanterix (QTRX) | United States | $0.753B | 0.00 |
| Omeros (OMER) | United States | $0.750B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.698B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.572B | 27.71 |
| Surmodics (SRDX) | United States | $0.543B | 78.88 |
| OraSure Technologies (OSUR) | United States | $0.531B | 24.43 |
| Meridian Bioscience (VIVO) | United States | $0.476B | 14.56 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.404B | 0.00 |
| Vapotherm (VAPO) | United States | $0.345B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.320B | 22.13 |
| BioLife Solutions (BLFS) | United States | $0.304B | 95.24 |
| Zynex (ZYXI) | United States | $0.250B | 25.67 |
| Bovie Medical (APYX) | United States | $0.236B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.227B | 0.00 |
| Owens & Minor (OMI) | United States | $0.198B | 4.20 |
| Chimerix (CMRX) | United States | $0.188B | 0.00 |
| United Health Products (UEEC) | United States | $0.175B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.170B | 0.00 |
| Female Health (VERU) | United States | $0.146B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.098B | 0.00 |
| United-Guardian (UG) | United States | $0.094B | 20.65 |
| InfuSystems Holdings (INFU) | United States | $0.090B | 0.00 |
| Surface Oncology (SURF) | United States | $0.075B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.060B | 20.75 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.058B | 0.00 |
| MRI INTERVENTNS (MRIC) | United States | $0.052B | 0.00 |
